Meeting Coverage

Although assessing and reducing the severity of tardive dyskinesia (TD)—a persistent and potentially disabling movement disorder linked with exposure to antipsychotics and other dopamine receptor blocking agents—is crucial for...

By: Cecilia Peterson; Amanda Glazar; Chirag Shah; Prakash Masand; Michael Lemon Introduction: Tardive Dyskinesia (TD) refers to abnormal, involuntary, choreoathetoid movements of the tongue, lips, face, trunk, and extremities...

Plasma neurofilament light chain (NfL) demonstrated to be a more valuable biomarker for neurodegeneration than total tau (T-tau) protein. This was the conclusion of the Mayo Clinic Study of Aging (MCSA), comparing the 2...

In patients who experienced a first clinical demyelinating event, baseline levels of serum neurofilament light chain (sNfL), a biomarker of neural damage, were associated with conversion to McDonald 2005 multiple sclerosis (MS)....

Preliminary results of a genome-wide-association study (GWAS) show a possible involvement of mast cells and neutrophils in the disease activity of relapsing-remitting MS patients [1]. These results provide important knowledge on...

A 3-year prospective observational study investigating ATP changes in MS via T7 MRSI, comparing patients with and without vascular disease risk factors (VDRF), demonstrated that VDRF-positive patients had lower brain ATP rates...

MS patients treated with anti-CD20 therapies ocrelizumab and rituximab have an increased risk of severe COVID-19 infection, whereas treatment with interferon or teriflunomide could reduce that risk. These were the preliminary...

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

Chirag Shah, PharmD Head, Strategic Publications & Medical Education Medical Affairs, Neurocrine Biosciences, Inc.   “In clinical trials for valbenazine, approved for treating tardive dyskinesia (TD)—a persistent and...